- Eli Lilly Stock Surges as Mounjaro and Zepbound Drugs Fuel Sales The Wall Street Journal
- Eli Lilly stock jumps on GLP-1 sales, end of manufacturing shortage Yahoo Finance
- Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar CNBC
- Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion Investors | Eli Lilly and Company
- Eli Lilly raises outlook on bumper sales of diabetes and weight loss drugs Financial Times
Credit: Source link


























